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particle vaccine against human papillomavirus types 16 and 
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Diane M Harper, Eduardo L Franco, Cosette M Wheeler, Anna-Barbara Moscicki, Barbara Romanowski, Cecilia M Roteli-Martins, David Jenkins, 
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Summary
Background Eﬀ ective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will require a high level of 
sustained protection against infection and precancerous lesions. Our aim was to assess the long-term eﬃ  cacy, 
immunogenicity, and safety of a bivalent HPV-16/18 L1 virus-like particle AS04 vaccine against incident and persistent 
infection with HPV 16 and HPV 18 and their associated cytological and histological outcomes. 
Methods We did a follow-up study of our multicentre, double-blind, randomised, placebo-controlled trial reported in 
2004. We included women who originally received all three doses of bivalent HPV-16/18 virus-like particle AS04 
vaccine (0·5 mL; n=393) or placebo (n=383). We assessed HPV DNA, using cervical samples, and did yearly cervical 
cytology assessments. We also studied the long-term immunogenicity and safety of the vaccine.  
Findings More than 98% seropositivity was maintained for HPV-16/18 antibodies during the extended follow-up phase. 
We noted signiﬁ cant vaccine eﬃ  cacy against HPV-16 and HPV-18 endpoints: incident infection, 96·9% (95% CI 
81·3–99·9); persistent infection: 6 month deﬁ nition, 94·3 (63·2–99·9); 12 month deﬁ nition, 100% (33·6–100). In a 
combined analysis of the initial eﬃ  cacy and extended follow-up studies, vaccine eﬃ  cacy of 100% (42·4–100) against 
cervical intraepithelial neoplasia (CIN) lesions associated with vaccine types. We noted broad protection against 
cytohistological outcomes beyond that anticipated for HPV 16/18 and protection against incident infection with HPV 45 
and HPV 31. The vaccine has a good long-term safety proﬁ le.
Interpretation Up to 4·5 years, the HPV-16/18 L1 virus-like particle AS04 vaccine is highly immunogenic and safe, 
and induces a high degree of protection against HPV-16/18 infection and associated cervical lesions. There is also 
evidence of cross protection. 
Introduction
Cervical cancer is the second most common malignant 
disease in women worldwide, and generally aﬀ ects 
individuals at a younger age than other cancers do.1,2 
Persistent infection with high-risk (oncogenic) human 
papillomavirus (HPV) genotypes is the main cause of 
cervical carcinogenesis.3,4 
The association between HPV and cervical cancer is 
unique; no other major human cancer has a single 
necessary cause.3,5 The relative risk of cervical cancer after 
infection with HPV, as indicated by the results of case-
control studies, is the strongest causal relation in cancer 
epidemiology identiﬁ ed to date.6,7 Establishment of the link 
between HPV and cervical cancer has provided the impetus 
for research into prophylactic vaccination against the most 
common HPV types associated with the disease—HPV 16 
and HPV 18. Initial studies have provided evidence that L1 
virus-like particle vaccines against HPV 16 and HPV 18 (as 
monovalent,8 bivalent,9 or quadrivalent10 vaccines) prevent 
at least 90% of incident and persistent infections and their 
associated precursors of cervical cancer. 
As predicted by mathematical modelling, the duration 
of protection provided by prophylactic HPV vaccination 
will be important in overall vaccine eﬀ ectiveness.11 Our 
aim, therefore, was to assess the long-term safety, 
immunogenicity, and eﬃ  cacy of a bivalent HPV-16/18 L1 
virus-like particle AS04 vaccine against incident and 
persistent infection with HPV 16 and HPV 18 and their 
associated cytological and histological outcomes. 
Methods 
Participants
Between November, 2003, and July, 2004, we enrolled 
women into the follow-up study of our double-blind, 
multicentre, randomised, placebo-controlled clinical 
trial,9 assessing the safety, immunogenicity, and eﬃ  cacy 
of a bivalent HPV-16/18 L1 virus-like particle AS04 vaccine 
against incident and persistent HPV-16/18 infections and 
their associated cytological and histological outcomes. 
Eligible women were those who participated in the initial 
eﬃ  cacy study, received all three doses of vaccine or 
placebo, and for whom treatment allocation remained 
double blinded. 
Written consent was mandatory for study participation 
and for study procedures, including colposcopy and loop 
electrosurgical excision. For girls younger than age 
18 years, we obtained parental permission as well as their 
assent. The study was done at 28 sites in North America 
(Canada and the USA) and Brazil. The ethics committees 
of all sites approved the study protocol. 
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Procedures
Figure 1 shows the overall study design, including initial 
and follow-up phases. Here, we describe analyses done 
on data obtained at three study visits that occurred over 
about 1 year in the on-going double-blind follow-up 
study. No vaccines were administered in the extended 
follow-up phase. 
In the initial eﬃ  cacy study, we administered three doses 
(0, 1, 6 month schedule) of the bivalent HPV-16/18 virus-
like particle AS04 vaccine (0·5 mL; GlaxoSmithKline 
Biologicals, Rixensart, Belgium), containing 20 μg each of 
HPV-16 and HPV-18 L1 virus-like particles produced on 
Spodoptera frugiperda Sf-9 and Trichoplusia ni Hi-5 cell 
substrate with AS04 adjuvant that contained 500 μg 
aluminum hydroxide and 50 μg 3-deacylated mono-
phosphoryl lipid A per dose provided in a monodose vial. 
The placebo contained 500 μg of aluminium hydroxide 
per dose, and was identical in appearance to the vaccine. 
Blinding of treatment allocation was maintained for all 
participating women, investigators, study personnel, and 
personnel from GlaxoSmithKline who were directly 
involved with the undertaking of the study.
We did immunogenicity assays as previously described9 
with minor changes to the dilution series. Brieﬂ y, we 
detected antibodies with a type-speciﬁ c ELISA, using 
type-speciﬁ c recombinant virus-like particles as coating 
antigens. During the extended follow-up phase, we 
collected serum from participants at months 0 and 12 
for assessment of immunogenicity. Seropositivity was 
deﬁ ned as a titre greater than or equal to the assay 
threshold established at 8 units/mL (EU/mL) for HPV 
16 and 7 EU/mL for HPV 18. We based time trends 
for seropositivity on geometric mean titres and 
corresponding 95% CIs. We identiﬁ ed the titres that 
resulted from natural infection by testing pre-vaccination 
blood samples obtained from women in the same 
countries as those in the initial study but who are 
participating in another ongoing HPV vaccine eﬃ  cacy 
study; the sera assessed were from women who were 
seropositive for HPV 16 or HPV 18 and HPV DNA 
negative for the same HPV type.
We used cervical samples for HPV DNA testing, which 
we did every 6 months as previously described.9 We 
assessed 14 high-risk HPV genotypes (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 66, and 68) and 11 low oncogenic 
risk HPV genotypes (6, 11, 34, 40, 42, 43, 44, 53, 54, 70, 
and 74), using the broad-spectrum PCR SPF10-LiPA system 
(version 1 Labo Biomedical Products, Rijswijk, 
Netherlands). In addition, we used type-speciﬁ c PCR 
methods for detection of HPV 16 and HPV 18 (all PCR 
analyses done at Delft Diagnostic Laboratory, Voorburg, 
Netherlands). We also used this PCR technology for HPV 
DNA testing in the biopsy samples. To reduce the risk of 
false-negative PCR results in the biopsy samples, the 
biopsy PCR testing algorithm included steps to prevent or 
remove inhibition, including microdissection of lesions, 
when appropriate, and dilution of samples.
Health-care providers collected cervical samples in 
PreservCyt medium (Cytyc Corporation, Boxborough, 
MA, USA) at 6-month intervals; no cervicovaginal samples 
were obtained in the follow-up phase of the study. A 
central laboratory (Quest Diagnostics, Teterboro, NJ, USA) 
assessed liquid-based cytological samples at month 0 and 
12. We did cytology assessments at 6-month intervals if 
previous ﬁ ndings showed atypical squamous cells and 
positivity by Hybrid Capture II (HCII; Digene Corp, 
Gaithersburg, MD, USA). We report results with the 2001 
Bethesda classiﬁ cation system.12
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Vaccine group 
Randomisation 
Placebo group 
Vaccination 
0–18/27 months 25/44–53 months (ongoing)
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Figure 1: Trial design
Follow-up time for each woman in each study phase varies dependent on when she completed her last study visit in the initial eﬃ  cacy study and when she entered the extended follow-up phase.
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With respect to colposcopy and treatment referral, 
protocol guidelines recommended colposcopy after two 
consecutive or intermittent reports of atypical squamous 
cells of undetermined signiﬁ cance (if HCII high-risk HPV 
DNA positive) or low-grade squamous intraepithelial 
lesions (independent of HPV DNA results), or one report 
of atypical glandular cells, atypical squamous cells cannot 
exclude high-grade squamous intraepithelial lesions, or 
high-grade squamous intraepithelial lesions. Biopsy was 
also required for any suspected lesions on colposcopy. 
Finally, guidelines directed excisional treatment for 
unexplained atypical glandular cells, biopsy results for 
adenocarcinoma in situ, and cervical intraepithelial 
neoplasia (CIN)2 or worse. 
We undertook histological diagnosis of formalin-ﬁ xed 
tissue specimens in two stages. A diagnosis for clinical 
management was made by at least two gynaecological 
histopathologists in a central laboratory. All diagnoses of 
CIN were conﬁ rmed by an independent re-examination 
of the tissue sections by a separate review panel of expert 
pathologists for endpoint determination. At least two 
members of the endpoint review panel identiﬁ ed and 
graded lesions by independent examination. If there was 
disagreement between diagnoses, a third expert 
pathologist examined the sections. The endpoint 
diagnoses were determined by a simple majority rule. We 
obtained digital images of the sections and marked the 
lesions to assist further dissection for PCR analyses. We 
sent this material to Delft  Diagnostics together with 
tissue blocks for sectioning and microdissection followed 
by HPV DNA testing. Any suspected change in histological 
grade or identiﬁ cation of additional lesions within the 
additional sections required re-examination by the 
endpoint review panel. We graded histological diagnosis 
as follows: CIN1+ was deﬁ ned as CIN1, 2, 3, 
adenocarcinoma in situ, and invasive carcinoma; CIN2+ 
included all listed CIN1+ categories, excluding CIN1. All 
study personnel remain blinded to HPV DNA test results, 
except HCII positive results, and were only informed of 
cytological and histological diagnoses for clinical 
management purposes.
We deﬁ ned incident cervical infection as the ﬁ rst 
detection of HPV 16, HPV 18, or other important high-
risk types (45, 31, 33, 52, and 58) in the liquid-based 
cytological sample. Persistent infection with HPV 16 or 
HPV 18 required at least one detection of the relevant 
HPV type in the cervical sample from the extended 
follow-up study. A 6-month deﬁ nition required the 
detection of the same HPV type in two consecutive 
assessments, with no negative sample in between, over a 
minimum of 5 months; a 12-month deﬁ nition required 
the detection of the same HPV type at consecutive 
assessments, with no negative samples in between, over 
a minimum of 10 months. 
Women reported as adverse events any new onset of 
chronic disease deﬁ ned according to guidelines of the 
Medical Dictionary for Regulatory Activities (MedDRA); 
conditions that prompted a visit to a doctor or an 
emergency room and not related to common diseases; 
and serious adverse events that occurred between the last 
visit of the initial eﬃ  cacy study and during the extended 
follow-up phase. Blinding continued for treatment 
allocation unless deemed essential for management of 
any safety event reported.
Our primary aim was to investigate long-term vaccine 
eﬃ  cacy in the prevention of incident HPV-16/18 infection 
in young women who participated in our initial eﬃ  cacy 
study.9 Our secondary objectives were to assess long-term 
vaccine eﬃ  cacy in the prevention of HPV-16/18 infections, 
Month 25–32* 
(n [ni])
Month 33–38* 
(n [ni])
Month 39–44* 
(n [ni])
Month 45–50* 
(n [ni])
Month 51–53* 
(n [ni])
Vaccine group
Visit 1 (n=393) 91 (91) 217 (217) 85 (85) 0 0
Visit 2 (n=377) 8 (0) 84 (0) 221 (0) 64 (0) 0
Visit 3 (n=367) 0 3 (3) 78 (77) 232 (230) 54 (53)
Placebo group
Visit 1 (n=383) 98 (98) 212 (212) 73 (73) 0 0
Visit 2 (n=371) 6 (0) 81 (0) 226 (0) 58 (0) 0
Visit 3 (n=365) 0 3 (3) 80 (80) 232 (231) 50 (50)
*Total follow-up from start of initial eﬃ  cacy study to month 12 extended follow-up. n (ni)=number of women who attended 
visit, according to month-interval (number of women who attended visit where evaluable blood sample collected). 
Table 1: Number of women who completed visits in extended follow-up phase, according to timing of 
visit relative to their enrolment in initial eﬃ  cacy study
Extended follow-up phase Combined initial eﬃ  cacy study and extended 
follow-up phase
Vaccine Placebo Vaccine Placebo 
Intention-to-treat analysis 393 383 560 553
According-to-protocol analysis 
Immunogenicity 310 249 384 344
Safety 373 371 540 541
Eﬃ  cacy 350 344 473 470
Numbers represent maximum potential eligible women for all analyses. However, some women might have been censored 
because of endpoint occurrence.
Table 2: Numbers of women, according to type of analysis
Initial eﬃ  cacy study Extended follow-up phase
Vaccine (n=560) Placebo (n=553) Vaccine (n=393) Placebo (n=383)
Age (years), mean (SD) 20·4 (2·8) 20·5 (2·7) 23·2 (2·9) 23·2 (2·8)
Region 
North America* 302 (54%) 305 (55%) 163 (41%) 165 (43%)
Brazil 258 (46%) 248 (45%) 230 (59%) 218 (57%)
Ethnic origin
White 389 (69%) 384 (69%) 251 (64%) 254 (66%)
Black 43 (8%) 41 (7%) 33 (8%) 29 (8%)
Asian 9 (2%) 4 (1%) 8 (2%) 5 (1%)
Other 119 (21%) 124 (22%) 101 (26%) 95 (25%)
Data are number (%) unless otherwise indicated. *Includes Canada and USA.
Table 3: Characteristics of women included in intention-to-treat analyses
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persistent for 6 months and 12 months; and cytological 
outcomes, including low-grade squamous intraepithelial 
lesions and high-grade squamous intraepithelial lesions, 
atypical squamous cells of undetermined signiﬁ cance, 
atypical squamous cells cannot exclude high-grade 
squamous intraepithelial lesions, and atypical glandular 
cells associated with HPV-16/18 infection. We also 
investigated vaccine eﬃ  cacy against incident infection 
associated with other high-risk types of HPV, and long-
term vaccine eﬃ  cacy in preventing histopathological 
endpoints, including CIN associated with HPV 16 or 
HPV 18. We added prevention of cytohistological 
outcomes independent of HPV DNA type post-hoc to the 
analyses. Other objectives included the assessment of 
persistence of vaccine-induced immune responses and 
long-term safety of the vaccine.
Statistical analysis
We estimated that a minimum of 500 women from the 
initial study would be needed to achieve 80% power to 
conﬁ rm that the lower limit of the 95% CI of the vaccine 
eﬃ  cacy estimate for incident infection was above 0 at the 
time of ﬁ nal study analysis, assuming a minimum of 
70% vaccine eﬃ  cacy.13 An α of 0·001 (two-sided test) was 
allocated for this interim analysis14 for eﬃ  cacy, safety, and 
immunogenicity. This α level was deﬁ ned on the basis of 
the expected number of analyses for the extended follow-
up data exclusively. We also present estimates of vaccine 
eﬃ  cacy for the combined data, including the initial and 
extended follow-up phases, with their associated p values. 
We did not use the latter for inferential purposes; they 
are given solely as further descriptors of the intervention 
eﬀ ects that are best represented by the vaccine eﬃ  cacy 
estimates and their respective 95% CIs.
We deﬁ ned four sets of analyses: intention-to-treat 
analysis and according-to-protocol analysis for women in 
the extended follow-up phase, and intention-to-treat 
analysis and according-to-protocol analysis for the 
combined cohorts from the initial eﬃ  cacy study and the 
extended follow-up phase. We censored women from 
assessment in the extended follow-up analyses if a deﬁ ned 
endpoint associated with HPV 16/18 occurred in the initial 
eﬃ  cacy study. We also censored women from type-speciﬁ c 
assessment if an incident infection associated with any 
other high-risk HPV type had been detected in the initial 
eﬃ  cacy study. In the combined analyses, follow-up time 
used to calculate vaccine eﬃ  cacy in the intention-to-treat 
analyses started at ﬁ rst vaccination (month 0 of the initial 
eﬃ  cacy study), and in the according-to-protocol analyses 
at the completion of vaccination (after 6 months) in the 
initial eﬃ  cacy study. An independent external statistician 
did the interim analysis to maintain study blinding. 
For the immunogenicity analysis, we included women 
with serology results who met study eligibility criteria 
and assessment criteria, and had at least one timepoint at 
which antibodies were detected for at least one vaccine 
antigen component. We excluded women from this 
analysis if HPV-16/18 infection had been detected at any 
point. We calculated 95% CI for seropositivity rates and 
geometric mean titres.
In the according-to-protocol analysis, we included all 
women in the extended follow-up phase who received 
three doses of HPV-16/18 L1 virus-like particle AS04 
vaccine or placebo, and who were negative for high-risk 
HPV DNA and seronegative for HPV 16 and HPV 18 at 
month 0, and negative for HPV-16 and HPV-18 DNA at 
month 6 in the initial eﬃ  cacy study. In the intention-to-
treat analyses, we included all women who had received 
at least one dose of study vaccine or placebo in the initial 
eﬃ  cacy study, and who had any data available for 
outcome measurement in the extended follow-up phase. 
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Figure 2: Geometric mean titres and seropositivity rates, according to HPV type and group in according-to-
protocol analyses for immunogenicity
%=proportion of women seropositive. Sera from all vaccinees and a small number of samples from the placebo 
group of the initial study were retested.
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For intention-to-treat analyses of eﬃ  cacy against 
incident infection with each individual high-risk HPV 
type, other than HPV 16/18, we included women who 
had received at least one vaccine dose and were HPV 
DNA negative for the speciﬁ c HPV type at month 0 in 
the initial study. The follow-up time for all eﬃ  cacy 
analyses ended at the time of an outcome event or at the 
last visit for which data were available. We express event 
rates as the number of cases divided by the accrued 
person-time since enrolment into the initial study. 
We used the conditional exact method to calculate 
vaccine eﬃ  cacy for HPV-16/18 infection, and for other 
oncogenic HPV types. This method controls for 
diﬀ erences in follow-up time between groups. We deﬁ ned 
vaccine eﬃ  cacy as one minus the ratio between the 
incidence rates in the vaccinated versus placebo groups, 
and the respective 95% CI descriptively measured the 
precision of the estimates. 
We tabulated safety event variables by the number of 
women who reported a symptom and the number of 
symptoms reported. For the analyses according to 
protocol, we included all enrolled women who complied 
with speciﬁ ed, minimum protocol requirements; for the 
intention-to-treat analyses we included women who had 
any safety data available.
We did all analyses with SAS (version 8.2; SAS Institute, 
Cary, North Carolina, USA) and ProcStatXact 5 (Cytel, 
Cambridge, MA, USA).
Role of the funding source
This study was funded and coordinated by GlaxoSmithKline 
Biologicals. Main investigators and co-investigators in the 
HPV Vaccine Study group obtained data for the study and 
cared for the patients. GlaxoSmithKline Biologicals did all 
HPV serological testing, Quest Diagnostics processed all 
cytology and histology specimens, and Delft Diagnostic 
Laboratory undertook PCR for HPV types. To ensure study 
blinding, all statistical analyses were done by external 
independent statisticians. The ﬁ ndings presented are 
included in the study report prepared by the sponsor and 
used for regulatory purposes. The corresponding author 
had full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results 
Of 776 women enrolled in the extended follow-up study 
(mean follow-up time 47·7 months, SD 3·4), 732 (94%) 
completed visit 3 (table 1). Table 2 shows the numbers of 
women included in the intention-to-treat and according-
to-protocol analyses. Table 3 shows the characteristics of 
the participants; the average age of participants was 
23 years (SD 3). We noted similar patterns of co-factors 
for HPV acquisition in women in the vaccine and placebo 
groups at entry into the extended follow-up phase of the 
study and at the last study visit (see webtable). 
More than 98% of women in the vaccine group were 
seropositive for HPV 16 and HPV 18 at every timepoint 
(ﬁ gure 2) during the extended follow-up phase of the 
study. We noted a decline in geometric mean titre values 
from peak responses 1 month after the third vaccine 
(month 7 of initial study) to a stable plateau beginning at 
month 18; overall there was a less than one log10 decline 
in geometric mean titre values from peak values to end 
of follow-up. There was at least a 133-fold diﬀ erence in 
Vaccine Placebo Vaccine eﬃ  cacy, 
% (95% CI)
p
Total  women Women reporting ≥1 
HPV-16/18 event
Event rate (95% CI)* Total women Women reporting ≥1 
HPV-16/18 event
Event rate (95% CI)*
According-to-protocol analyses of extended follow-up phase (vaccine: n=350, placebo: n=344)
HPV 16 311 1 0·2 (0·0–0·9) 280 21 4·0 (2·5–6·2) 95·8 (73·6–99·9) <0·0001
HPV 18 310 0 0·0 (0·0–0·6) 291 11 2·0 (1·0–3·5) 100·0 (62·1–100) 0·0003
HPV 16/18 310 1 0·2 (0·0–0·9) 277 28 5·6 (3·7–8·1) 96·9 (81·3–99·9) <0·0001
Intention-to-treat analyses of extended follow-up phase (vaccine: n=393, placebo: n=383)
HPV 16 353 2 0·3 (0·0–1·1) 322 25 4·2 (2·7–6·2) 92·7 (70·9–99·2) <0·0001
HPV 18 356 0 0·0 (0·0–0·5) 332 12 1·9 (1·0–3·3) 100·0 (65·6–100·0) 0·0001
HPV 16/18 352 2 0·3 (0·0–1·1) 313 31 5·5 (3·7–7·8) 94·4 (77·9–99·3) <0·0001
According-to-protocol analyses of combined initial and follow-up phase (vaccine: n=473, placebo: n=470)
HPV 16 414 1 0·1 (0·0–0·6) 385 40 4·5 (3·2–6·2) 97·7 (86·6–99·9) <0·0001
HPV 18 414 2 0·2 (0·0–0·7) 385 17 1·9 (1·1–3·0) 88·9 (53·3–98·8) 0·0002
HPV 16/18 414 3 0·3 (0·1–0·9) 385 51 5·9 (4·4–7·7) 94·7 (83·5–98·9) <0·0001
Intention-to-treat analyses of combined initial and follow-up phase (vaccine: n=560, placebo: n=553)
HPV 16 481 7 0·5 (0·2–1·1) 470 55 4·4 (3·3–5·8) 88·0 (73·6–95·4) <0·0001
HPV 18 481 3 0·2 (0·0–0·6) 470 29 2·3 (1·5–3·2) 90·0 (67·8–98·1) <0·0001
HPV 16/18 481 9 0·7 (0·3–1·3) 470 73 6·0 (4·7–7·5) 88·5 (77·0–95·0) <0·0001
*Per 100 person-years: number of cases divided by accrued person-time.
Table 4: Vaccine eﬃ  cacy for incident HPV-16/18 infections, in cervical samples
See Online for webtable
Articles
1252 www.thelancet.com   Vol 367   April 15, 2006
geometric mean titre values between the vaccine and 
placebo groups for both HPV 16 and HPV 18 at the end 
of the extended follow-up period. The geometric mean 
titre values associated with naturally-acquired HPV-16 
infection were 36·3 EU/mL (95% CI 33·8–38·9) and for 
HPV-18 26·5 (24·5–28·8). Vaccine-induced geometric 
mean titres at 51–53 months were about 17-fold and 14-
fold higher in HPV-16 and HPV-18 infections, respectively, 
than noted for natural infection.
We noted signiﬁ cant long-term vaccine eﬃ  cacy against 
incident HPV-16/18 infections in all of the extended follow-
up analyses a mean of 42 months after completion of the 
vaccination schedule (table 4). Likewise, in the combined 
initial and extended follow-up study analyses, we noted 
high levels of vaccine eﬃ  cacy through a mean follow-up 
period of 47·7 months after entry to initial study. 
We noted a high level of vaccine eﬃ  cacy with both the 
6-month and 12-month deﬁ nitions of persistent HPV-16 
and HPV-18 infections in the follow-up study and in 
analyses of the two study phases combined, although 
not all ﬁ ndings were signiﬁ cant because of the limited 
number of events (table 5). One woman in the vaccine 
group had a 6-month persistent HPV-16 infection 
detected at the last two timepoints of the follow-up study. 
Vaccine eﬃ  cacy against 12-month persistent infection 
with HPV 16/18 was 100% in the combined initial and 
follow-up analysis that was done per-protocol. We also 
noted substantial vaccine eﬃ  cacy in preventing 6-month 
and 12-month persistent HPV-18 infection irrespective 
of the type of analyses. 
As shown in table 6, the HPV-16/18 L1 virus-like particle 
AS04 vaccine was highly eﬃ  cacious against cytological 
abnormalities (atypical squamous cells of undetermined 
signiﬁ cance or worse and low-grade squamous 
intraepithelial lesions or worse) associated with 
HPV 16/18, in the combined analyses of initial and follow-
up phases. We continue to note 100% vaccine eﬃ  cacy 
against all histological abnormalities associated with HPV 
16/18. We detected no lesions related to HPV 18. Table 6 
also shows substantial vaccine eﬃ  cacy against abnormal 
Deﬁ nition of 
persistence 
(months)
Vaccine Placebo Vaccine eﬃ  cacy, 
% (95% CI)
p
Total 
women 
Women reporting ≥1 
HPV-16/18 event 
Event rate (95% CI)* Total 
women 
Women reporting ≥1 
HPV-16/18 event 
Event rate (95% CI)*
According-to-protocol analyses of extended follow-up phase (vaccine: n=350, placebo: n=344)
HPV 16 6 311 1 0·2 (0·0 to 0·9) 287 12 2·2 (1·1 to 3·8) 92·3 (47·7 to 99·8) 0·0012
HPV 18 6 311 0 0·0 (0·0 to 0·6) 295 5 0·9 (0·3 to 2·0) 100·0 (–5·5 to 100·0) 0·0269
HPV 16/18 6 311 1 0·2 (0·0 to 0·9) 287 16 3·0 (1·7 to 4·8) 94·3 (63·2 to 99·9) <0·0001
HPV 16 12 311 0 0·0 (0·0 to 0·6) 295 5 0·9 (0·3 to 2·0) 100·0 (–5·2 to 100·0) 0·0269
HPV 18 12 311 0 0·0 (0·0 to 0·6) 295 2 0·3 (0·0 to 1·2) 100·0 (–419·4 to 100·0) 0·2366
HPV 16/18 12 311 0 0·0 (0·0 to 0·6) 295 7 1·2 (0·5 to 2·5) 100·0 (33·6 to 100·0) 0·0062
Intention-to-treat analyses of extended follow-up phase (vaccine: n=393, placebo: n=383)
HPV 16 6 357 1 0·1 (0·0 to 0·8) 331 16 2·6 (1·5 to 4·1) 94·2 (62·4 to 99·9) <0·0001
HPV 18 6 358 0 0·0 (0·0 to 0·5) 342 6 0·9 (0·3 to 2·0) 100·0 (16·5 to 100·0) 0·0133
HPV 16/18 6 357 1 0·1 (0·0 to 0·8) 329 19 3·1 (1·9 to 4·8) 95·2 (69·6 to 99·9) <0·0001
HPV 16 12 357 0 0·0 (0·0 to 0·5) 341 8 1·2 (0·5 to 2·4) 100·0 (43·0 to 100·0) 0·0031
HPV 18 12 358 0 0·0 (0·0 to 0·5) 344 3 0·4 (0·1 to 1·3) 100·0 (–141 to 100·0) 0·1171
HPV 16/18 12 357 0 0·0 (0·0 to 0·5) 340 10 1·5 (0·7 to 2·8) 100·0 (57·0 to 100·0) 0·0007
According-to-protocol analyses of combined initial and follow-up phase (vaccine: n=473, placebo: n=470)
HPV 16 6 414 1 0·1 (0·0 to 0·6) 385 19 2·1 (1·2 to 3·2) 95·1 (69·2 to 99·9) <0·0001
HPV 18 6 414 0 0·0 (0·0 to 0·4) 385 5 0·5 (0·2 to 1·2) 100·0 (–3·5 to 100·0) 0·0256
HPV 16/18 6 414 1 0·1 (0·0 to 0·6) 385 23 2·5 (1·6 to 3·8) 96·0 (75·2 to 99·9) <0·0001
HPV 16 12 414 0 0·0 (0·0 to 0·4) 385 7 0·7 (0·3 to 1·5) 100·0 (34·3 to 100·0) 0·0059
HPV 18 12 414 0 0·0 (0·0 to 0·4) 385 2 0·2 (0·0 to 0·8) 100·0 (–408·2 to 100·0) 0·2319
HPV 16/18 12 414 0 0·0 (0·0 to 0·4) 385 9 1·0 (0·4 to 1·8) 100·0 (52·2 to 100·0) 0·0013
Intention-to-treat analyses of combined initial and follow-up phase (vaccine: n=560, placebo: n=553)
HPV 16 6 481 2 0·1 (0·0 to 0·5) 470 29 2·3 (1·5 to 3·2) 93·4 (74·0 to 99·2) <0·0001
HPV 18 6 481 0 0·0 (0·0 to 0·3) 470 8 0·6 (0·3 to 1·2) 100·0 (42·8 to 100·0) 0·0035
HPV 16/18 6 481 2 0·1 (0·0 to 0·5) 470 34 2·7 (1·8 to 3·7) 94·4 (78·2 to 99·4) <0·0001
HPV 16 12 481 1 0·1 (0·0 to 0·4) 470 13 1·0 (0·5 to 1·7) 92·5 (50·3 to 99·8) 0·0008
HPV 18 12 481 0 0·0 (0·0 to 0·3) 470 3 0·2 (0·0 to 0·7) 100·0 (–138·0 to 100·0) 0·1203
HPV 16/18 12 481 1 0·1 (0·0 to 0·4) 470 16 1·2 (0·7 to 2·0) 94·0 (61·1 to 99·9) 0·0001
*Per 100 person-years: number of cases divided by accrued person–time.
Table 5: Vaccine eﬃ  cacy for persistent HPV-16/18 infections, in cervical samples 
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cytological and histological outcomes associated with any 
high-risk HPV type and independently of HPV DNA 
status. Table 7 shows substantial vaccine eﬃ  cacy against 
incident infection with HPV 45 and HPV 31.
More women in the placebo group than in the vaccine 
group reported adverse events and new onset of chronic 
diseases (table 8). A comparable number of women in 
both vaccine and placebo groups reported serious adverse 
events; none was judged related, or possibly related, to 
vaccination. No one died.
Discussion
Our ﬁ ndings indicate that the HPV-16/18 L1 virus-like 
particle AS04 vaccine has sustained long-term vaccine 
eﬃ  cacy against incident and persistent infections 
associated with HPV 16 and HPV 18. The results show 
sustained immune response and long-term eﬃ  cacy 
against HPV-16 and HPV-18 infection, including 
persistence up to 12 months, and against related 
cytohistological outcomes as well as providing evidence of 
broader protection against cytohistological outcomes and 
cross-protection against HPV 45 and HPV 31. The vaccine 
has a good safety record.
The AS04 adjuvant system used to formulate the vaccine 
could be contributing to the maintenance of the sustained 
immune response. Clinical trials of other vaccines also 
show higher antibody titres when adjuvanted with AS04 
than with aluminum alone.15,16
 Endpoint Vaccine Placebo Vaccine eﬃ  cacy, % (95% CI) p
Total women Women reporting an event Total women Women reporting an event
HPV 16 ≥ASCUS 505 1 497 32 97·0 (82·2 to 99·9) <0·0001
≥LSIL 505 1 497 22 95·6 (73·0 to 99·9) <0·0001
CIN1+ 481 0 470 8 100·0 (42·4 to 100·0) 0·0035
CIN2+ 481 0 470 5 100·0 (–7·7 to 100·0) 0·0292
HPV 18 ≥ASCUS 505 1 497 17 94·3 (63·8 to 99·9) <0·0001
≥LSIL 505 1 497 6 83·8 (–33·7 to 99·6) 0·0674
CIN1+ 481 0 470 0 NA NA
CIN2+ 481 0 470 0 NA NA
HPV 16/18 ≥ASCUS 505 2 497 44 95·7 (83·5 to 99·5) <0·0001
≥LSIL 505 2 497 26 92·6 (70·5 to 99·2) <0·0001
CIN1+ 481 0 470 8 100·0 (42·4 to 100·0) 0·0035
CIN2+ 481 0 470 5 100·0 (–7·7 to 100·0) 0·0292
Any high-risk HPV type* ≥ASCUS 505 53 497 95 48·4 (27·0 to 63·8) 0·0001
≥LSIL 505 30 497 61 53·4 (26·7 to 71·0) 0·0006
CIN1+ 481 8 470 19 58·7 (1·3 to 84·4) 0·0315
CIN2+ 481 3 470 9 67·1 (–31·9 to 94·3) 0·0869
Independent of HPV DNA status† ≥ASCUS 505 90 497 138 39·8 (20·9 to 54·4) 0·0002
≥LSIL 505 41 497 70 44·6 (17·4 to 63·3) 0·0034
CIN1+ 505 12 497 24 51·5 (–0·9 to 77·9) 0·0418
CIN2+ 505 3 497 11 73·3 (–1·0 to 95·2) 0·0327
ASCUS (atypical squamous cells of undetermined signiﬁ cance) and LSIL (low-grade squamous intraepithelial lesions) refer to cytological outcomes; CIN refers to histological outcomes based on cervicovaginal (initial study) and 
cervical samples (initial study and extended follow-up) combined. CIN1+ is deﬁ ned as CIN1, 2, 3, and invasive cell carcinoma (ICC), and CIN2+ is CIN2, CIN3, and ICC. *Includes HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
66, and 68. Total number of events include multiple type infections, which may or may not include HPV 16 or HPV 18 single or combined infections. †Includes outcomes also associated with low-risk types and HPV DNA negative.
Table 6: Overview of combined initial and extended follow-up vaccine eﬃ  cacy against cytological and histological endpoints 
Vaccine Placebo Vaccine eﬃ  cacy (%) (95% CI)
Total women Women reporting ≥1 event of 
HPV 45, HPV 31, HPV 33, HPV 52, or 
HPV 58 and who did not report the 
same event in initial study
Event rate (95% CI)* Total women  Women reporting ≥1 event of 
HPV 45, HPV 31, HPV 33, HPV 52, 
or HPV 58 and who did not report 
the same event in initial study
Event rate (95% CI)*
HPV 45 528 1 0·1 (0·0 to 0·4) 518 17 1·2 (0·7 to 1·9) 94·2 (63·3 to 99·9)
HPV 31 528 14 0·9 (0·5 to 1·6) 516 30 2·1 (1·4 to 3·0) 54·5 (11·5 to 77·7)
HPV 33 529 12 0·8 (0·4 to 1·4) 519 13 0·9 (0·5 to 1·5) 8·6 (–117·3 to 61·9)
HPV 52 524 40 2·8 (2·0 to 3·8) 515 48 3·5 (2·6 to 4·6) 18·6 (–26·5 to 47·8)
HPV 58 529 14 0·9 (0·5 to 1·6) 517 16 1·1 (0·6 to 1·8) 14·0 (–87·9 to 61·1)
*Per 100 person-years: number of cases divided by accrued person–time.
Table 7: Vaccine eﬃ  cacy against incident infection with HPV 45, HPV 31, HPV 52, HPV 33, and HPV 58 in cervical samples from intention-to-treat analyses
Articles
1254 www.thelancet.com   Vol 367   April 15, 2006
We noted a high degree of protection against both 
incident and persistent infections of at least 6 months 
and 12 months duration up to 4·5 years of follow-up in 
the combined assessment of the initial and extended 
follow-up studies. The high degree of protection lends 
support to the notion that persistent HPV infection is a 
valid virological endpoint in the clinical assessment of 
HPV vaccines.17 Given that persistent HPV infection is a 
valid intermediate endpoint for the development of high-
grade dysplasia and cervical cancer, the high level of 
eﬃ  cacy seen here against persistent infection might 
ultimately lead to the long-term prevention of HPV-16 
and HPV-18 associated precancerous and cancerous 
lesions. 
It is noteworthy that persistent HPV-16 infection was 
consistently detected in the cytology samples preceding 
all instances of CIN detected. The continued use of the 
SPF10-LiPA system followed by type-speciﬁ c PCR allowed 
for consistency of HPV detection between cytological and 
histological specimens, reducing the possibility of 
misclassiﬁ cation of HPV status.
Our clinical management algorithm allowed for a 
suﬃ  cient amount of time before tissue sampling to 
improve the distinction between naturally regressing 
lesions and the progressing clinically signiﬁ cant HPV-16 
and HPV-18 precancerous lesions. This algorithm required 
colposcopy referral after two atypical squamous cells of 
undeﬁ ned signiﬁ cance (if high-risk HPV positive) or two 
cytology reports of low-grade squamous intraepithelial 
lesions, which probably resulted in detection of a high 
proportion of clinically important and persistent cervical 
lesions and avoided the overdiagnosis and overtreatment 
of frequently regressing CIN1 and CIN2 lesions.18 The few 
observations of CIN in the extended follow-up phase 
might reﬂ ect the time it takes to develop true persistent 
high-grade cervical dysplasia.19 The main limitation of this 
study is the few observations of CIN in the extended 
follow-up phase, which might reﬂ ect the time it takes to 
develop true persistent high-grade cervical dysplasia.17
Reports on the safety of HPV vaccines have focused 
on standard safety variables, such as injection site and 
solicited and unsolicited and general and serious adverse 
events. Here, we present safety data for this bivalent 
HPV-16/18 L1 virus-like particle AS04 vaccine up to 
53 months. Additionally, our observations of vaccine 
safety are consistent with the clinically acceptable safety 
proﬁ le of other AS04-based vaccines.20 We noted that 
more women on placebo than women who received the 
vaccine reported at least one adverse event. One possible 
explanation for this ﬁ nding is that the women who 
received the vaccine had fewer cytological abnormalities 
that required diagnostic follow-up; controls probably 
attended more colposcopy sessions, providing an 
increased opportunity to report adverse events. 
When we estimated vaccine eﬃ  cacy against cytological 
or histological endpoints associated with all high-risk 
HPV types and independent of HPV status, we noted 
protection that seems to extend beyond the degree of 
eﬀ ect that might be explained simply by protection 
against HPV-16/18 endpoints alone. Analyses of vaccine 
eﬃ  cacy against incident infection with other important 
oncogenic HPV types indicate a high degree of protection 
against HPV 45 and protection against HPV 31, the third 
and fourth most common HPV types associated with 
cervical cancers. Analyses of lesions associated with high-
risk types other than HPV 16 and HPV 18 are confounded 
by a high frequency of multiple infections, however, 
including HPV 16 and HPV 18. Cross protection against 
other oncogenic HPV types by HPV-16/18 vaccination 
has not been shown in other clinical trials of HPV 
vaccines. Results of studies of natural HPV infection 
have shown type-speciﬁ c response with some serological 
cross reactivity between phylogenetically related types.21–23 
Besides serological cross reactivity, another possible 
immune mechanism is the cell-mediated T-helper cell 
response.24 Additional data and analyses are needed to 
ascertain the importance of cross-protection on lesion 
development and to establish an understanding of the 
mechanisms that underlie cross protection. 
In conclusion, immunisation with the HPV-16/18 L1 
virus-like particle vaccine adjuvanted with AS04 induces 
sustained high levels of antibodies that provide protection 
against HPV-16 and HPV-18 associated endpoints for up 
to 4·5 years. These ﬁ ndings set the stage for the widescale 
adoption of HPV vaccination for prevention of cervical 
cancer.
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